Deciphera Pharmaceuticals

KS - LawrencePharmaceutical1 H-1B visas (FY2023)

Focus: Deciphera Pharmaceuticals is a small molecule-focused pharmaceutical company headquartered in Lawrence, Kansas, specializing in neurology therapeutics. The company operates as a dedicated drug developer in a specialized therapeutic area.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Deciphera Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Deciphera Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ripretinib

GIST - Gastrointestinal Stromal Tumor

N/A

Clinical Trials (1)

NCT04148092Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

N/A

Help build intelligence for Deciphera Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (neurology) allows for deep scientific expertise development in a growing market
Small molecule specialty provides exposure to a foundational drug modality with broad applicability
Kansas headquarters offers potential for lower cost of living relative to coastal biotech hubs

Watch Out For

No active clinical trials (0 Phase 1/2/3 programs) suggests limited near-term catalysts or early-stage pipeline activity
Zero current job openings indicate no active hiring or potential organizational contraction

Generated by Claude from Deciphera Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Tenosynovial Giant Cell Tumor

N/A

Clinical Trials (1)

NCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

N/A

Ripretinib

GIST - Gastrointestinal Stromal Tumor

N/A

Clinical Trials (1)

NCT06619275Ripretinib (QINLOCK®) According to Current SmPC

N/A

Rebastinib

Breast Cancer

Phase 1

Clinical Trials (1)

NCT02824575Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Phase 1

Vimseltinib

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07158398Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Phase 1

DCC-2036

Chronic Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT00827138Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

Phase 1

Inlexisertib

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT04892017Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1

Ripretinib

GIST - Gastrointestinal Stromal Tumor

Phase 1

Clinical Trials (1)

NCT04530981A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Phase 1

Vimseltinib

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07539090Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Phase 1

DCC-2618

Gastrointestinal Stromal Tumors

Phase 1

Clinical Trials (1)

NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Phase 1

DCC-3084

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT06287463Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Phase 1

DCC-2701 tablet

Locally Advanced Tumors

Phase 1

Clinical Trials (1)

NCT02228811A Study of DCC-2701 in Participants With Advanced Solid Tumors

Phase 1

Vimseltinib

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07158411Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Phase 1

DCC-2812

Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT06966024Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Phase 1

Rebastinib

Locally Advanced or Metastatic Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT03717415A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2

Vimseltinib

Advanced Malignant Neoplasm

Phase 1/2

Clinical Trials (1)

NCT03069469Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Phase 1/2

Rebastinib

Locally Advanced or Metastatic Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT03601897A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2

DCC-3009

Gastrointestinal Stromal Tumor (GIST)

Phase 1/2

Clinical Trials (1)

NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Phase 1/2

Ripretinib

Gastrointestinal Stromal Tumors

Phase 1/2

Clinical Trials (1)

NCT05080621Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Phase 1/2

Inlexisertib

GIST

Phase 1/2

Clinical Trials (1)

NCT05957367A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Phase 1/2

Vimseltinib

Chronic Graft-Versus-Host Disease (cGVHD)

Phase 2

Clinical Trials (1)

NCT06619561A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Phase 2

Ripretinib

GIST

Phase 3

Clinical Trials (1)

NCT05734105A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Phase 3

Ripretinib

Gastrointestinal Stromal Tumors

Phase 3

Clinical Trials (1)

NCT03673501A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Phase 3

Sapablursen

Polycythemia Vera

Phase 3

Vimseltinib

Tenosynovial Giant Cell Tumor

Phase 3

Clinical Trials (1)

NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Phase 3

DCC-2618

Gastrointestinal Stromal Tumors

Phase 3

Clinical Trials (1)

NCT03353753Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 25 clinical trials

Top TAs: Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

19 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub